95. Novel Antifungal Olorofim Use in Intractable CNS and Non-CNS Disseminated Coccidioidomycosis
Authors: Donovan Fariba , Thompson George R , Johnson Royce H , Kuran Rasha , Patterson Thomas F , Hoenigl Martin , Schaenman Joanna M , Shoham Shmuel , Holland Steven M , Sikka Monica K , Spec Andrej , Bresnik Mark , Galgiani John N , Rex John H 
Published: January 2025

Background

Disseminated coccidioidomycosis (DCM) requires long courses of antifungal treatment. Olorofim, a novel antifungal in development, selectively blocks pyrimidine biosynthesis by inhibiting fungal dihydroorotate dehydrogenase (DHODH), and we evaluated its impact on clinical and mycologic response in patients with refractory DCM.

Methods

Adults &gt;18y with limited or no treatment options enrolled in NCT03583164 (Study 32), an open label olorofim Phase 2b study. A Main Phase of 84+6 days was followed by an Extension Phase; we report here outcomes through 1 year.

Results

41 DCM patients enrolled at 10 US sites from 05/2019 to 08/2022. Median age was 47y (range 21-72y). 30 (73.2%) had CNS disease, of whom 13 (43%) had ventriculoperitoneal shunt or Ommaya reservoir. Median time from DCM diagnosis to olorofim initiation was 936d (range 47d to 8y). Median (mean) olorofim treatment was 353d (382d).

Data Review Committee (DRC)-adjudicated EORTC-MSG was Partial Clinical Response (PCR) in 28 (68.3%) at Day 42 and 27 (65.9%) at Day 84. Complete Clinical Response (CCR) was in 3 (7.3%) at both timepoints. Constitutional findings (fever, malaise) often resolved within 4 weeks. Integrated Overall Response (Clinical + Mycologic + Imaging) was 0% at Day 42 & 84 due to slow resolution of serologic findings of DCM, even in patients with CCR. Patients in the Extension Phase had PCR or CCR ranging 52.6% to 65.8% with lower rates due, in part, to missing data at study visit dates being assessed as failures, in addition to the fluctuating clinical status of DCM patients over time.

Hepatic injury, judged at least possibly related to olorofim was 9 (22.0%) in Main Phase, was managed by dose reduction/pause, and led to discontinuation in 1 (2.4%) patient. Non-serious and self-limited GI symptoms were noted in 16 patients (39%) of which 1 (2.4%) was related to olorofim. Three deaths during Extension Phase were not attributed to olorofim.

Conclusion

Olorofim has a positive benefit-risk profile in DCM patients with no or limited treatment options. Favorable Clinical Responses were seen in 73.2% and often sustained through 1 year of treatment. Hepatic injury was usually manageable with monitoring. Future studies should assess earlier use of olorofim in serious DCM.

Disclosures

Fariba Donovan, MD/PhD, F2G: Grant/Research Support George R. Thompson, III, MD, Astellas: Advisor/Consultant|Cidara: Advisor/Consultant|Cidara: Grant/Research Support|F2G: Advisor/Consultant|F2G: Grant/Research Support|Melinta: Advisor/Consultant|Melinta: Grant/Research Support|Mundipharma: Advisor/Consultant|Mundipharma: Grant/Research Support|Pfizer: Advisor/Consultant Thomas F. Patterson, MD, F2G: Grant/Research Support Martin Hoenigl, MD, Aicuris: Advisor/Consultant|Astra Zeneca: Honoraria|Gilead: Grant/Research Support|Gilead: Honoraria|IMMY: Grant/Research Support|Melinta: Grant/Research Support|Melinta: Honoraria|MSD: Grant/Research Support|Mundipharma: Grant/Research Support|Mundipharma: Honoraria|Pfizer: Grant/Research Support|Pulmocide: Advisor/Consultant|Pulmocide: Grant/Research Support|Scynexis: Advisor/Consultant|Scynexis: Grant/Research Support|Shionogi: Honoraria Joanna M. Schaenman, MD, PhD, FAST, Eurofins Viracor: Honoraria|F2G: Grant/Research Support|MedCure: Advisor/Consultant|Moderna: Clinical trial support to institution|OneLegacy: Advisor/Consultant Shmuel Shoham, MD, F2G: Grant/Research Support Monica K. Sikka, MD, F2G: Grant/Research Support Andrej Spec, MD, MSCI, F2G: Grant/Research Support Mark Bresnik, MD, F2G Ltd: Employee John H. Rex, MD, F2G: Employee